XFOR X4 Pharmaceuticals, Inc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501697 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY73.7%
TTM net income YoY15.3%
TTM EPS YoY106.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin68.8%
Operating margin-812.0%
Net margin-813.3%
FCF margin—
EBITDA margin-794.1%
Returns
ROE-80.3%
ROA-40.7%
ROIC (approx.)-134.7%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.54x
Current ratio13.22x
Interest coverage-9.26x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.80M | $2.40M | $2.50M | $2.20M | $1.60M | $1.70M | $900,000 | $1.50M |
| Cost of revenue | $513,000 | $1.62M | $598,000 | $364,000 | $351,000 | $326,000 | $4.72M | $302,000 |
| Gross profit | $2.29M | $783,000 | $1.90M | $1.84M | $1.25M | $1.37M | -$3.82M | $1.20M |
| R&D expense | $13.34M | $15.08M | $15.45M | $18.52M | $17.34M | $18.35M | $18.51M | $21.70M |
| SG&A expense | $9.01M | $8.50M | $6.97M | $7.38M | $11.59M | $9.53M | $15.02M | $15.14M |
| Operating income | -$19.99M | -$16.39M | -$20.31M | -$23.70M | -$27.51M | -$26.23M | -$9.44M | -$35.72M |
| Interest expense | $2.19M | $2.16M | $2.13M | $2.19M | $2.26M | $2.23M | $2.20M | $2.30M |
| Pretax income | -$20.20M | -$16.16M | -$20.24M | -$23.93M | -$29.84M | -$25.70M | $316,000 | -$39.56M |
| Income tax | $3,000 | $2,000 | $0 | $0 | -$30,000 | $37,000 | $34,000 | $258,000 |
| Net income | -$20.20M | -$16.16M | -$20.24M | -$23.93M | -$29.82M | -$25.74M | $282,000 | -$39.82M |
| EBITDA | -$19.66M | -$15.39M | -$20.08M | -$23.48M | -$27.29M | -$25.88M | -$8.97M | -$35.44M |
| EPS (basic) | -0.16 | -0.13 | -0.16 | — | -0.69 | -3.47 | 0.04 | — |
| EPS (diluted) | -0.16 | -0.13 | -0.16 | — | -0.69 | -3.47 | 0.04 | — |
| Weighted avg. shares (diluted) | 126.52M | 126.34M | 126.29M | — | 43.27M | 7.41M | 6.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $185.80M | $195.09M | $216.91M | $217.05M | $70.44M | $40.02M | $41.04M | $56.48M |
| Receivables | $1.47M | $2.05M | $1.11M | $573,000 | $891,000 | $1.15M | $509,000 | $1.07M |
| Inventory | $5.51M | $5.50M | $4.64M | $4.48M | $4.08M | $3.17M | $3.09M | $2.82M |
| Current assets | $198.13M | $218.85M | $241.98M | $261.58M | $132.81M | $72.94M | $95.70M | $112.17M |
| PP&E, net | $57,000 | $111,000 | $146,000 | $182,000 | $218,000 | $254,000 | $487,000 | $776,000 |
| Goodwill | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M |
| Intangibles | $12.82M | $13.10M | $9.06M | $9.25M | $9.44M | $9.62M | $9.81M | $10.00M |
| Total assets | $231.82M | $253.06M | $270.28M | $290.46M | $163.56M | $105.17M | $130.01M | $146.45M |
| Current liabilities | $14.98M | $19.37M | $23.77M | $25.76M | $23.51M | $22.90M | $25.88M | $32.88M |
| Long-term debt | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M |
| Total debt | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M |
| Total liabilities | $92.93M | $97.61M | $101.83M | $104.17M | $101.94M | $101.20M | $107.07M | $124.30M |
| Shareholders' equity | $138.88M | $155.45M | $168.45M | $186.29M | $61.62M | $3.97M | $22.94M | $22.15M |
| Net debt | -$110.80M | -$120.09M | -$141.91M | -$142.05M | $4.57M | $34.98M | $33.96M | $18.52M |
| Shares outstanding | 100.90M | 96.11M | 94.32M | 90.91M | 25.15M | 7.96M | 5.79M | 5.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$20.19M | -$20.79M | -$19.60M | -$15.53M | -$27.82M | -$29.90M | -$12.37M | -$32.99M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $41,000 |
| Free cash flow | — | — | — | -$15.53M | -$27.82M | -$29.90M | -$12.37M | -$33.04M |
| Investing cash flow | $11.00M | -$1.00M | $19.25M | $16.85M | -$28.67M | $23.11M | -$3.14M | -$8.62M |
| Financing cash flow | -$112,000 | $75,000 | $2,000 | $146.09M | $86.91M | $5.63M | $0 | $135,000 |
| Depreciation & amortization | $331,000 | $997,000 | $223,000 | $223,000 | $223,000 | $355,000 | $476,000 | $273,000 |
| Stock-based compensation | $3.50M | $3.09M | $2.41M | $2.27M | $760,000 | $748,000 | $519,000 | $2.22M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.